524715.BO - Sun Pharmaceutical Industries Limited

BSE - BSE Real Time Price. Currency in INR
+1.70 (+0.29%)
At close: 3:57PM IST
Stock chart is not supported by your current browser
Previous close576.40
Bid0.00 x 0
Ask0.00 x 0
Day's range572.15 - 583.95
52-week range572.15 - 583.95
Avg. volumeN/A
Market cap1.389T
PE ratio (TTM)43.87
EPS (TTM)13.18
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters2 months ago

    Sun Pharma posts profit dive on U.S. pricing pressure

    REUTERS - India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other ...

  • Reuters5 months ago

    Sun Pharma reports first-quarter loss as generics business suffers

    India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a surprise quarterly loss on Friday due to one-off legal costs and pressure over prices in its largest market, the United States, casting a shadow over its growth prospects. Sun is the latest maker of generic drugs to report poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the United States. India's drugs industry, the world's fourth largest, has been hit particularly hard due also to challenges at home, where the government is tightening control over prices, and a nationwide tax reform has hit supplies.

  • IANS5 months ago

    Sun Pharma reports huge net loss for Q1

    Mumbai, Aug 11 (IANS) Sun Pharmaceutical Industries Ltd on Friday reported a huge net loss of Rs 1,291 crore for the first quarter (Q1) of fiscal 2017-18 on standalone basis, which is over eight times the net loss of Rs 152 crore incurred in the same period year ago. In a regulatory filing on the BSE, the leading drug maker said standalone revenue from operations for the quarter under review (Q1) was flat at Rs 1,803 crore as against Rs 1,800 crore in the like period year ago. Sequentially, revenue declined 11 per cent in Q1 from Rs 2,017 crore quarter ago when the net profit was Rs 95 crore.

  • IANS7 months ago

    USFDA approves Sun Pharma's generic ezetimibe tablets

    Mumbai, June 13 (IANS) Drug major Sun Pharmaceutical Industries on Tuesday announced that one of its wholly owned subsidiaries has received final approval from the US Food and Drug Administration (USFDA) ...

  • Sun Pharma says 2018 sales may fall as U.S. market gets tougher
    Reuters8 months ago

    Sun Pharma says 2018 sales may fall as U.S. market gets tougher

    India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers. "The U.S. generics industry is facing rapidly changing market dynamics, (and) increased competitive intensity and customer consolidation is leading to pressure on pricing," Sun's Managing Director Dilip Shanghvi said on a call with analysts after the company reported lower than expected fourth-quarter earnings.

  • IANS8 months ago

    USFDA accepts Biological License Application from Sun Pharma

    Mumbai, May 24 (IANS) Drug major Sun Pharmaceutical Industries Ltd on Wednesday said the US Food and Drug Administration (USFDA) has accepted its Biological License Application (BLA) for tildrakizumab. In a statement issued here Sun Pharmaceuticals said the USFDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. "The acceptance of the regulatory filing by the US FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis," Abhay Gandhi, CEO - North America Business, Sun Pharmaceuticals, was quoted as saying in the statement.

  • Reuters10 months ago

    Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

    India's largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company's biggest market after four years. The move would come as a boost to Sun, whose U.S. growth has been hit over the past year as five of its plants face supply restrictions due to regulatory issues. Sun said on Tuesday the U.S. Food and Drug Administration (FDA) had informed it about the agency's plans to lift the ban on Mohali.

  • Reuters11 months ago

    Sensex reverses gains as investors book profit

    REUTERS - Indian shares retreated from near two-year highs to end lower on Thursday as investors booked profit in pharmaceutical and realty stocks such as Sun Pharmaceutical Industries and DLF Ltd. The ...

  • Reuters11 months ago

    Sun Pharma's profits drop as U.S. sales hit by pricing, supply issues

    Sun Pharmaceutical Industries, India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, as pricing issues and supply constraints affected sales in the United States, its largest market. Sun's U.S. business faces increasing uncertainty as it struggles to fix quality control problems found by regulators at its key drug factories, and is the subject of a U.S. Department of Justice investigation into increases in drug prices. "The idea for us is to improve our supply and regain market share ... our plan is to create a very successful specialty business," billionaire founder and Managing Director Dilip Shanghvi told analysts on a conference call.